Skip to main content
. Author manuscript; available in PMC: 2024 Mar 2.
Published in final edited form as: Cancer Chemother Pharmacol. 2023 Mar 2;91(3):281–290. doi: 10.1007/s00280-023-04511-0

Table 1.

Patient characteristics (20 treated patients)

Gender
 Female 10
 Male 10
Race
 Asian 1
 Black or African-American 3
 White 16
Ethnicity
 Hispanic or Latino 1
 Non-Hispanic 19
Age (years)
 Median 64
 Range 32–77
Performance status
 0 1
 1 16
 2 3
Diagnosis
 AML 18
 MDS 2
AML ELN risk stratification
 Intermediate 7
 Adverse 8
 Unknown 3
No. prior regimens
 Median 2
 Range 1–6